Cargando…

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer

Preclinical works have suggested cytotoxic chemotherapies may increase the number of cancer stem cells (CSC) whereas angiogenesis inhibition may decrease CSC proliferation. We developed a proof of concept clinical trial to explore bevacizumab activity on breast CSC. Breast cancer patients requiring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabatier, Renaud, Charafe-Jauffret, Emmanuelle, Pierga, Jean-Yves, Curé, Hervé, Lambaudie, Eric, Genre, Dominique, Houvenaeghel, Gilles, Viens, Patrice, Ginestier, Christophe, Bertucci, François, Sfumato, Patrick, Extra, Jean-Marc, Gonçalves, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572380/ https://www.ncbi.nlm.nih.gov/pubmed/31064127 http://dx.doi.org/10.3390/jcm8050612

Ejemplares similares

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
por: Sabatier, Renaud, et al.
Publicado: (2021)

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
por: Boudin, Laurys, et al.
Publicado: (2016)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study
por: Rahal, S., et al.
Publicado: (2015)

Are there candidates for high-dose chemotherapy in ovarian carcinoma?
por: Sabatier, Renaud, et al.
Publicado: (2012)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
por: Gonçalves, Anthony, et al.
Publicado: (2016)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

Breast cancer stem cells: tools and models to rely on
por: Charafe-Jauffret, Emmanuelle, et al.
Publicado: (2009)

Targeting breast cancer stem cells: fishing season open!
por: Ginestier, Christophe, et al.
Publicado: (2010)

p53 and cancer stem cells: The mevalonate connexion
por: Ginestier, Christophe, et al.
Publicado: (2012)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
por: Tabouret, Emeline, et al.
Publicado: (2016)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2018)

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
por: Guégan, Jean-Philippe, et al.
Publicado: (2021)

8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer
por: Bertucci, François, et al.
Publicado: (2012)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Production of CRISPRi-engineered primary human mammary epithelial cells with baboon envelope pseudotyped lentiviral vectors
por: Pastor, Sonia, et al.
Publicado: (2023)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings
por: Rioualen, Claire, et al.
Publicado: (2017)

The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling
por: Lopez Almeida, Leonor, et al.
Publicado: (2018)

Transperitoneal para-aortic lymphadenectomy by robot assisted laparoscopy in 10 steps
por: Heinemann, Mellie, et al.
Publicado: (2019)

Choosing the most appropriate minimally invasive approach to treat gynecologic cancers in the context of an enhanced recovery program: Insights from a comprehensive cancer center
por: Netter, Antoine, et al.
Publicado: (2020)

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
por: Ben Hamida, Azza, et al.
Publicado: (2008)

Enhanced Recovery after Surgery and Endometrial Cancers: Results from an Initial Experience Focused on Elderly Patients
por: Miguet, Céline, et al.
Publicado: (2023)

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
por: Letessier, Anne, et al.
Publicado: (2006)

Molecular characterization of breast cell lines: a tool for breast cancer studies
por: Charafe-Jauffret, E, et al.
Publicado: (2005)

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
por: Planes-Laine, Gabrielle, et al.
Publicado: (2019)

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

CD25(high) Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
por: Fattori, Stéphane, et al.
Publicado: (2023)

Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling
por: Korkaya, Hasan, et al.
Publicado: (2009)

Nectin-4 is a new histological and serological tumor associated marker for breast cancer
por: Fabre-Lafay, Stéphanie, et al.
Publicado: (2007)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study
por: Houvenaeghel, Gilles, et al.
Publicado: (2022)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5cfa6t8lak45tij9ihtcpldj3u